Imaging Vascular Properties of Pediatric Brain Tumors Using Ferumoxytol and Gadolinium in a Single Imaging Session
Current imaging techniques often do not demonstrate the true amount and location of brain tumors, which are both critical factors for treatment decision-making. This purpose of this study is to assess the safety and effectiveness of a new iron containing agent called "ferumoxytol" in improving our ability to image pediatric brain tumors. Ferumoxytol, as well as the usual contrast agent, gadolinium, together will be used to image the blood vessels in pediatric brain tumors. After contrast agent injection into the veins, special magnetic resonance imaging (MRI) scans will be performed to see changes in blood vessels in the brain and tumor.
Patients will be scanned at five different time-points (5 MRI series). Each patient will have a baseline MRI study (gadolinium only, with no ferumoxytol). MRI scans with both ferumoxytol and gadolinium contrast will be performed beginning at least 3 weeks after the baseline scan. The timing of all MRIs will not occur more frequently than every 3 weeks, and all five ferumoxytol/gadolinium scans will take place within 2 years from study entry. There will be a final outpatient clinic visit approximately 1 month after the final ferumoxytol/gadolinium MRI.
Measurements such as size of tumor, blood flow to tumor (perfusion), and leakiness of blood vessels within the tumor (permeability) will be described at each time-point and the information will be evaluated throughout the study. The tumor size will be evaluated by 2 radiologists.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Oregon Health & Science University
OHSU Knight Cancer Institute
Results (where available)
- Source: http://clinicaltrials.gov/show/NCT00978562
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Neoplasms By Site
A collective term for precoordinated organ/neoplasm headings locating neoplasms by organ, as BRAIN NEOPLASMS; DUODENAL NEOPLASMS; LIVER NEOPLASMS; etc.
Cerebral Ventricle Neoplasms
Neoplasms located in the brain ventricles, including the two lateral, the third, and the fourth ventricle. Ventricular tumors may be primary (e.g., CHOROID PLEXUS NEOPLASMS and GLIOMA, SUBEPENDYMAL), metastasize from distant organs, or occur as extensions of locally invasive tumors from adjacent brain structures.
Brain Stem Neoplasms
Benign and malignant intra-axial tumors of the MESENCEPHALON; PONS; or MEDULLA OBLONGATA of the BRAIN STEM. Primary and metastatic neoplasms may occur in this location. Clinical features include ATAXIA, cranial neuropathies (see CRANIAL NERVE DISEASES), NAUSEA, hemiparesis (see HEMIPLEGIA), and quadriparesis. Primary brain stem neoplasms are more frequent in children. Histologic subtypes include GLIOMA; HEMANGIOBLASTOMA; GANGLIOGLIOMA; and EPENDYMOMA.
Primary and metastatic (secondary) tumors of the brain located above the tentorium cerebelli, a fold of dura mater separating the CEREBELLUM and BRAIN STEM from the cerebral hemispheres and DIENCEPHALON (i.e., THALAMUS and HYPOTHALAMUS and related structures). In adults, primary neoplasms tend to arise in the supratentorial compartment, whereas in children they occur more frequently in the infratentorial space. Clinical manifestations vary with the location of the lesion, but SEIZURES; APHASIA; HEMIANOPSIA; hemiparesis; and sensory deficits are relatively common features. Metastatic supratentorial neoplasms are frequently multiple at the time of presentation.
This protocol revision seeks to expand upon the data originally collected from 12 patients who received ferumoxytol. The results of the original protocol were published in 2007 in Neurosur...
In this study the investigators would like to compare special magnetic resonance (MR) brain imaging techniques (called: dynamic perfusion, blood-brain barrier (BBB) permeability measuremen...
In this study the investigators would like to find out how a new iron containing Magnetic Resonance Imaging (MRI) contrast agent, called "ferumoxytol" can help the investigators to assess...
This study will define the effects of ferumoxytol on electrocardiogram (ECG) data as well as evaluate pharmacokinetics
This crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.
Purpose An analysis of reported adverse events (AEs) among patients using i.v. iron products, including the newer agent ferumoxytol, is presented. Methods All AE reports to the Food and Drug Administr...
Bhawan J (2011) Histopathology Non-melanocytic mimics of melanocytic neoplasms Abstract: On histopathologic examination, many non-neoplastic conditions mimic benign or malignant neoplasms. Alternat...
With the exception of lymphoma involving the spleen, other primary and secondary neoplasms are rare and infrequently encountered. Primary malignant neoplasms involving the spleen are lymphoma and angi...
Pancreatic neuroendocrine neoplasms are uncommon but rising in incidence. There have been recent changes in the WHO nomenclature and a newly proposed American Joint Committee on Cancer TNM staging, wh...
Background/Aims: Many studies have suggested that hyperplastic polyps (HPs) are associated with adenomas and even malignancy. We investigated whether or not HPs are associated with the presence of syn...